EcoDrugPlus

Phosphodiesterase 9a

Ensembl ID : ENSDLEG00000021086
Gene Symbol: PDE9A
3 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSDLEG00000011992
Gene Symbol: PIK3R1
3 Cross references
259 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSDLEG00000005809
Gene Symbol: PIK3R2
3 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSDLEG00000014101
Gene Symbol: PIK3R3
1 Cross references
276 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSDLEG00000013375
Gene Symbol: PIK3R5
3 Cross references
255 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSDLEG00000005864
Gene Symbol: PLA2G5
3 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSDLEG00000000800
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSDLEG00000005595
Gene Symbol: PLA2G10
1 Cross references
250 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSDLEG00000020738
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSDLEG00000013736
Gene Symbol: PLG
3 Cross references
269 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSDLEG00000021369
Gene Symbol: PLAT
3 Cross references
203 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSDLEG00000013349
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).